Liver function tests and fibrosis scores in a rural population in Africa: a cross-sectional study to estimate the burden of disease and associated risk factors

Objectives Liver disease is a major cause of morbidity and mortality in sub-Saharan Africa, but its prevalence, distribution and aetiology have not been well characterised. We therefore set out to examine liver function tests (LFTs) and liver fibrosis scores in a rural African population. Design We undertook a cross-sectional survey of LFTs. We classified abnormal LFTs based on reference ranges set in America and in Africa. We derived fibrosis scores (aspartate aminotransferase (AST) to Platelet Ratio Index (APRI), fibrosis-4, gamma-glutamyl transferase (GGT) to platelet ratio (GPR), red cell distribution width to platelet ratio and S-index). We collected information about alcohol intake, and infection with HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV). Setting We studied a population cohort in South-Western Uganda. Participants Data were available for 8099 adults (median age 30 years; 56% female). Results The prevalence of HBV, HCV and HIV infection was 3%, 0.2% and 8%, respectively. The prevalence of abnormal LFTs was higher based on the American reference range compared with the African reference range (eg, for AST 13% vs 3%, respectively). Elevated AST/ALT ratio was significantly associated with self-reported alcohol consumption (p<0.001), and the overall prevalence of AST/ALT ratio >2 was 11% (suggesting alcoholic hepatitis). The highest prevalence of fibrosis was predicted by the GPR score, with 24% of the population falling above the threshold for fibrosis. There was an association between the presence of HIV or HBV and raised GPR (p=0.005) and S-index (p<0.001). By multivariate analysis, elevated LFTs and fibrosis scores were most consistently associated with older age, male sex, being under-weight, HIV or HBV infection and alcohol consumption. Conclusions Further work is required to determine normal reference ranges for LFTs in this setting, to evaluate the specificity and sensitivity of fibrosis scores and to determine the aetiology of liver disease.

[1]  G. Asiki,et al.  Liver function tests and fibrosis scores in a rural population in Africa , 2020 .

[2]  V. Suvannarerg,et al.  Prospective comparison of transient elastography, point shear wave elastography, APRI and FIB‐4 for staging liver fibrosis in chronic viral hepatitis , 2019, Journal of viral hepatitis.

[3]  G. Asiki,et al.  Liver function tests and fibrosis scores in a rural population in Africa: estimation of the burden of disease and associated risk factors , 2019 .

[4]  S. Vento,et al.  Liver cirrhosis in sub-Saharan Africa: neglected, yet important. , 2018, The Lancet. Global health.

[5]  P. Klenerman,et al.  Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort , 2018, BMC Infectious Diseases.

[6]  Assessment of liver fibrosis in Egyptian chronic hepatitis B patients: A comparative study including 5 noninvasive indexes: Erratum , 2018, Medicine.

[7]  R. Goldin,et al.  Unexplained chronic liver disease in Ethiopia: a cross-sectional study , 2018, BMC Gastroenterology.

[8]  M. Tag-Adeen,et al.  Assessment of liver fibrosis in Egyptian chronic hepatitis B patients , 2018, Medicine.

[9]  B. Jia,et al.  Non‐invasive fibrosis markers for chronic hepatitis B in sub‐Saharan Africa , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[10]  Alan D. Lopez,et al.  The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.

[11]  K. Marsh,et al.  Hepatitis B virus infection as a neglected tropical disease , 2017, bioRxiv.

[12]  N. Berhe,et al.  Are non‐invasive fibrosis markers for chronic hepatitis B reliable in sub‐Saharan Africa? , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[13]  H. Whittle,et al.  Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study. , 2016, The Lancet. Global health.

[14]  Oscar J L Mitchell,et al.  The pathophysiology of thrombocytopenia in chronic liver disease , 2016, Hepatic medicine : evidence and research.

[15]  M. Sonderup,et al.  Health disparities in liver disease in sub‐Saharan Africa , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[16]  C. Obirikorang,et al.  Hepatic Enzyme Alterations in HIV Patients on Antiretroviral Therapy: A Case-Control Study in a Hospital Setting in Ghana , 2015, PloS one.

[17]  G. Cooke,et al.  The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa , 2015, Gut.

[18]  R. Nsubuga,et al.  Prevalence of Dyslipidaemia and Associated Risk Factors in a Rural Population in South-Western Uganda: A Community Based Survey , 2015, PloS one.

[19]  J. Vaughan,et al.  Prevalence and causes of thrombocytopenia in an academic state-sector laboratory in Soweto, Johannesburg, South Africa. , 2015, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[20]  A. Murray,et al.  A systematic review of the prevalence of mildly abnormal liver function tests and associated health outcomes , 2015, European journal of gastroenterology & hepatology.

[21]  S. Barakat,et al.  Non alcoholic fatty liver disease (NAFLD) in a Sudanese population: What is the prevalence and risk factors? , 2014, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology.

[22]  Q. Anstee,et al.  Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging , 2013, Frontline Gastroenterology.

[23]  R. Nsubuga,et al.  Sociodemographic distribution of non-communicable disease risk factors in rural Uganda: a cross-sectional study. , 2013, International journal of epidemiology.

[24]  K. Sikaris,et al.  The de ritis ratio: the test of time. , 2013, The Clinical biochemist. Reviews.

[25]  Xianzhang Huang,et al.  First Definition of Reference Intervals of Liver Function Tests in China: A Large-Population-Based Multi-Center Study about Healthy Adults , 2013, PloS one.

[26]  B. Ye,et al.  RDW to Platelet Ratio: A Novel Noninvasive Index for Predicting Hepatic Fibrosis and Cirrhosis in Chronic Hepatitis B , 2013, PloS one.

[27]  William M. Lee,et al.  Diagnosis of alcohol misuse and alcoholic liver disease among patients in the medical emergency admission service of a large urban hospital in Sub-Saharan Africa; a cross sectional study , 2013, The Pan African medical journal.

[28]  S. Kinde,et al.  Robust reference intervals for Liver function test (LFT) analytes in newborns and infants , 2012, BMC Research Notes.

[29]  S. Lewin,et al.  Human immunodeficiency virus infection and the liver. , 2012, World journal of hepatology.

[30]  Philip Hall,et al.  What is the Real Function of the Liver ‘Function’ Tests? , 2012, The Ulster medical journal.

[31]  C. Onyekwere,et al.  Non-alcoholic fatty liver disease and the metabolic syndrome in an urban hospital serving an African community. , 2011, Annals of hepatology.

[32]  Ying Sun,et al.  Performance of the aspartate aminotransferase‐to‐platelet ratio index for the staging of hepatitis C‐related fibrosis: An updated meta‐analysis , 2011, Hepatology.

[33]  B. Aktas,et al.  Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease , 2011, Hepatitis monthly.

[34]  C. Thio,et al.  Liver disease in the HIV-infected individual. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[35]  T. Aw,et al.  Liver Function Tests (LFTs) , 2010 .

[36]  Yan Liu,et al.  Global Burden of Aflatoxin-Induced Hepatocellular Carcinoma: A Risk Assessment , 2010, Environmental health perspectives.

[37]  S. Caldwell,et al.  Epidemiology and natural history of non-alcoholic steatohepatitis. , 2009, Clinics in liver disease.

[38]  J. L. Fuentes-Allen,et al.  Correlation between HIV viral load and aminotransferases as liver damage markers in HIV infected naive patients: a concordance cross-sectional study , 2009, Virology Journal.

[39]  Peter J. Hotez,et al.  Neglected Tropical Diseases in Sub-Saharan Africa: Review of Their Prevalence, Distribution, and Disease Burden , 2009, PLoS neglected tropical diseases.

[40]  A. Kamali,et al.  CLSI-Derived Hematology and Biochemistry Reference Intervals for Healthy Adults in Eastern and Southern Africa , 2009, PloS one.

[41]  T. Sparer,et al.  Feeling manipulated: cytomegalovirus immune manipulation , 2009, Virology Journal.

[42]  J. Goedert,et al.  Aflatoxin Exposure and Viral Hepatitis in the Etiology of Liver Cirrhosis in The Gambia, West Africa , 2008, Environmental health perspectives.

[43]  R. Sterling,et al.  The Prevalence and Risk Factors for Abnormal Liver Enzymes in HIV-Positive Patients without Hepatitis B or C Coinfections , 2008, Digestive Diseases and Sciences.

[44]  A. Kamali,et al.  Baseline Morbidity in 2,990 Adult African Volunteers Recruited to Characterize Laboratory Reference Intervals for Future HIV Vaccine Clinical Trials , 2008, PloS one.

[45]  B. Neuschwander‐Tetri,et al.  Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels. , 2008, Archives of internal medicine.

[46]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[47]  P. Hyltoft Petersen,et al.  The Nordic Reference Interval Project 2000: recommended reference intervals for 25 common biochemical properties , 2004, Scandinavian journal of clinical and laboratory investigation.

[48]  J. Limdi,et al.  Evaluation of abnormal liver function tests , 2003, Postgraduate medical journal.

[49]  G. Indolfi Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection , 2018 .

[50]  D. Guwatudde,et al.  Alcohol use among adults in Uganda: findings from the countrywide non-communicable diseases risk factor cross-sectional survey. , 2016, Global health action.

[51]  Joel Z Stengel,et al.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.

[52]  Wilhelm Kirch,et al.  Encyclopedia of public health , 2008 .